A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT

被引：70

作者：

Bryant, J. L. ^{[1
]}

Britson, J. ^{[1
]}

Balko, J. M. ^{[1
]}

Willian, M. ^{[1
]}

Timmons, R. ^{[1
]}

Frolov, A. ^{[2
]}

Black, E. P. ^{[1
,3
]}

机构：

[1] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA

[2] Univ Alabama, Ctr Comprehens Canc, Lab Surg, Birmingham, AL 35294 USA

[3] Univ Kentucky, Ctr Comprehens Canc, Markey Canc Ctr, Lab Surg, Lexington, KY 40536 USA

来源：

BRITISH JOURNAL OF CANCER | 2012年 / 106卷 / 01期

关键词：

biomarker; targeted therapy; invasion; metastasis; GROWTH-FACTOR RECEPTOR; LUNG-CANCER; MESENCHYMAL TRANSITION; KINASE INHIBITORS; SENSITIVITY; PHENOTYPE; RESISTANCE; CARCINOMA; METASTASIS; DETERMINES;

D O I：

10.1038/bjc.2011.465

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: Treatment with epidermal growth factor receptor (EGFR) inhibitors can result in clinical response in non-small-cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) for some unselected patients. EGFR and KRAS mutation status, amplification of EGFR, or gene expression predictors of response can forecast sensitivity to EGFR inhibition. METHODS: Using an NSCLC cell line model system, we identified and characterised microRNA (miRNA) gene expression that predicts response to EGFR inhibition. RESULTS: Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and tumours, and discriminates primary from metastatic tumours. Signature genes target proteins that are enriched for epithelial-to-mesenchymal transition (EMT) genes. Epithelial-to-mesenchymal transition predicts EGFR inhibitor resistance and metastatic behaviour. The EMT transcription factor, ZEB1, shows altered expression in erlotinib-sensitive NSCLC and PDAC, where many signature miRNA genes are upregulated. Ectopic expression of mir-200c alters expression of EMT proteins, sensitivity to erlotinib, and migration in lung cells. Treatment with TGF beta vertical bar changes expression of signature miRNA and EMT proteins and modulates migration in lung cells. CONCLUSION: From these data, we hypothesise that the tumour microenvironment elicits TGF beta vertical bar and stimulates a miRNA gene expression program that induces resistance to anti-EGFR therapy and drives lung tumour cells to EMT, invasion, and metastasis. British Journal of Cancer (2012) 106, 148-156. doi:10.1038/bjc.2011.465 www.bjcancer.com Published online 1 November 2011 (C) 2012 Cancer Research UK

引用

页码：148 / 156

页数：9

共 34 条

[1] miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy [J].

Adam, Liana ;

Zhong, Meng ;

Choi, Woonyoung ;

Qi, Wei ;

Nicoloso, Milena ;

Arora, Ameeta ;

Calin, George ;

Wang, Hua ;

Siefker-Radtke, Arlene ;

McConkey, David ;

Bar-Eli, Menashe ;

Dinney, Colin .

CLINICAL CANCER RESEARCH, 2009, 15 (16) :5060-5072

[2] MicroRNA functions in animal development and human disease [J].

Alvarez-Garcia, I ;

Miska, EA .

DEVELOPMENT, 2005, 132 (21) :4653-4662

[3] Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors [J].

Balko, Justin M. ;

Potti, Anil ;

Saunders, Christopher ;

Stromberg, Arnold ;

Haura, Eric B. ;

Black, Esther P. .

BMC GENOMICS, 2006, 7 (1)

[4] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].

Bartel, David P. .

CELL, 2007, 131 (04) :11-29

[5] Sensitivity to epidermal growth factor receptor inhibitor requires E-cedherin expression in urothelial carcinoma cells [J].

Black, Peter C. ;

Brown, Gordon A. ;

Inamoto, Teruo ;

Shrader, Marissa ;

Arora, Ameeta ;

Siefker-Radtke, Arlene O. ;

Adam, Liana ;

Theodorescu, Dan ;

Wu, Xifeng ;

Munsell, Mark F. ;

Bar-Eli, Menashe ;

McConkey, David J. ;

Dinney, Colin P. N. .

CLINICAL CANCER RESEARCH, 2008, 14 (05) :1478-1486

[6] A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells [J].

Burk, Ulrike ;

Schubert, Joerg ;

Wellner, Ulrich ;

Schmalhofer, Otto ;

Vincan, Elizabeth ;

Spaderna, Simone ;

Brabletz, Thomas .

EMBO REPORTS, 2008, 9 (06) :582-589

[7] Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non-Small Cell Lung Cancer [J].

Ceppi, Paolo ;

Mudduluru, Giridhar ;

Kumarswamy, Regalla ;

Rapa, Ida ;

Scagliotti, Giorgio V. ;

Papotti, Mauro ;

Allgayer, Heike .

MOLECULAR CANCER RESEARCH, 2010, 8 (09) :1207-1216

[8] Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines [J].

Coldren, Christopher D. ;

Helfrich, Barbara A. ;

Witta, Samir E. ;

Sugita, Michio ;

Lapadat, Razvan ;

Zeng, Chan ;

Baron, Anna ;

Franklin, Wilbur A. ;

Hirsch, Fred R. ;

Geraci, Mark W. ;

Bunn, Paul A., Jr. .

MOLECULAR CANCER RESEARCH, 2006, 4 (08) :521-528

[9] TGF-β signaling in tumor suppression and cancer progression [J].

Derynck, R ;

Akhurst, RJ ;

Balmain, A .

NATURE GENETICS, 2001, 29 (02) :117-129

[10] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

← 1 2 3 4 →